AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER).

How it works

Aminosyn II 5% with electrolytes in dextrose 25% provides amino acids for protein synthesis, dextrose for caloric supply, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.

What the body does with it

Metabolism	Amino acids are metabolized via deamination, transamination, and urea cycle; dextrose metabolized via glycolysis and oxidative phosphorylation; electrolytes are excreted or utilized as needed.
Excretion	Renal: amino acids and dextrose metabolites excreted primarily as urea, CO2, and water; electrolytes excreted renally with fractional excretion varying by individual needs; no significant biliary or fecal elimination.
Half-life	Not applicable as a single entity; component amino acids have half-lives ranging from minutes (e.g., alanine) to hours (e.g., branched-chain amino acids); dextrose half-life ~1.5-2 hours in normal glucose metabolism; clinical context: continuous infusion maintains steady state.
Protein binding	Minimal for amino acids (<10%) and dextrose (<5%); electrolytes have negligible protein binding; calcium is ~40% bound to albumin and globulins.
Volume of Distribution	Amino acids: 0.3-0.5 L/kg (total body water); dextrose: 0.2 L/kg (extracellular water); calcium: 0.2 L/kg (extracellular); overall Vd approximates total body water (~0.6 L/kg).
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: immediate (within seconds) for hemodynamic and metabolic effects; clinical effect (e.g., caloric support) occurs within minutes of initiating infusion.
Duration of Action	Intravenous: duration is directly tied to infusion rate and metabolic clearance; effects last as long as infusion continues; after discontinuation, metabolic effects subside within minutes to hours (glucose homeostasis within 1-2 hours).

Classification & Brands

Dosing & administration

Intravenous; initial adult dose 1.0 g/kg/day of amino acids, up to 1.5 g/kg/day; dextrose rate 5 mg/kg/min initially, titrate to 7 mg/kg/min; daily dose adjusted based on metabolic requirements, electrolytes as per serum levels.

Dosage form	INJECTABLE
Renal impairment	GFR 30-59 mL/min: reduce amino acid dose by 50% (max 0.7 g/kg/day); GFR 15-29 mL/min: reduce to 0.5 g/kg/day; GFR <15 mL/min: contraindicated unless on dialysis, then 0.5-1.0 g/kg/day with monitoring.
Liver impairment	Child-Pugh A: reduce amino acid dose by 25% (0.75-1.0 g/kg/day); Child-Pugh B: reduce by 50% (0.5-0.75 g/kg/day), avoid if encephalopathy; Child-Pugh C: contraindicated.
Pediatric use	Infants and children: 2-3 g/kg/day of amino acids, dextrose starting at 5-10 mg/kg/min, titrated based on blood glucose; electrolytes as per daily requirements; monitor fluid balance.
Geriatric use	Start at lower end of dosing (amino acids 0.8-1.0 g/kg/day, dextrose 3-5 mg/kg/min) due to reduced renal function, monitor electrolytes and fluid balance closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Breastfeeding	Excreted in human milk: Unknown. Large molecular weight of amino acids and dextrose likely limits transfer. M/P ratio: Not established. Caution if used during breastfeeding, especially in high doses or prolonged therapy; monitor infant for metabolic disturbances.
Teratogenic Risk	Amino acids, dextrose, and electrolytes are considered standard components of parenteral nutrition and are not associated with teratogenic risk when used appropriately. No specific teratogenicity reported. However, underlying maternal conditions requiring this therapy may pose risks. Use in pregnancy only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

Not for use in patients with severe electrolyte imbalances, anuria, or in patients with known hypersensitivity to any component. Risk of fluid overload, electrolyte disturbances, and hyperglycemia.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Severe electrolyte imbalances","Anuria","Hyperglycemia"]

Clinical Precautions

Precautions	["Monitor fluid status, serum electrolytes, blood glucose, and renal function frequently","Risk of hyperglycemia, especially in diabetic patients","Risk of electrolyte imbalances, including hypercalcemia","Avoid rapid infusion to prevent fluid overload","Use with caution in patients with cardiac or renal impairment"]
Food/Dietary	No oral food interactions apply as this is an intravenous formulation. However, concurrent oral intake (if any) should be managed to avoid overfeeding or electrolyte imbalances.

Clinical Tips & Counseling

Drug interactions

Loading safety data…